
    
      The duration of study participation for each participant will be approximately 30 to 60 days,
      including 2 or 3 visits (1 or 2 vaccination visit) and 1 or 2 telephone calls, depending on
      study Group.

      * This is the first dose of 9vHPV, of the 2-dose or 3-dose series according to the local
      recommendations and age of the participant. These additional vaccinations for the completion
      of 9vHPV schedule will take place outside of the objectives and scope of this study and thus
      will not be described in this protocol.
    
  